An interventional study of Exercise and TDCS in Spinal Pain Syndrome and Chronic Pain (Back / Neck), sponsored by Fundación Universidad Católica de Valencia San Vicente Mártir. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Fundación Universidad Católica de Valencia San Vicente Mártir · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies in Chronic Pain with a site in Spain — 34 open to participants now, 40 under way, 1 of them phase 3. Chronic Pain · Spain.
Among the 174 studies in Chronic Pain with a site in Spain, this one is the 109th largest by planned enrollment of the 141 interventional ones that give a count, is one of 19 that started in 2025, is one of 126 with no phase, reaches primary completion later than 21 of the 39 other live ones, and was the 148th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →34 of the 174 studies in Chronic Pain with a site in Spain are open now. Recruiting first, the newest first:
Biobizkaia Health Research Institute · Sites in Spain
Ages 35–75
Bernardino Clavo, MD, PhD · Sites in Spain
Ages 18+
University of Salamanca · Sites in Spain
Ages 65+
Investigación en Hemofilia y Fisioterapia · Sites in Spain
Ages 18+ · Men only
Hospital Clinico Universitario San Cecilio · Sites in Spain
Ages 18–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 9 · Phase 4 3
First in 2003; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 66 across the 141 interventional studies, 268 across the 33 observational. Of the 113 that completed or were terminated, 17 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 174 have an industry lead sponsor. The 10 most frequent:
Fundación Universidad Católica de Valencia San Vicente Mártir is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
Fundación Universidad Católica de Valencia San Vicente Mártir has 3 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
8 of the studies in Chronic Pain with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07693998University of ValenciaPain Neuroscience Education for Chronic Pain | 2026-12-31 |
| NCT07467408Consorci Sanitari de TerrassaTreatment of Mechanical Low Back Pain With High-Intensity Focused Ultrasound (HIFU) | 2026-12-31 |
| NCT07498569Universidad Miguel Hernandez de ElcheEffects of Percutaneous Electrical Stimulation in Patients With Chronic Supraspinatus Tendinopathy | 2027-06-01 |
| NCT07420387Investigación en Hemofilia y FisioterapiaEffectiveness of an Educational Program for Pain Management in Patients With Hemophilic Arthropathy | 2027-06-28 |
| NCT07313280University of MalagaCentral Sensitization Syndromes and Post-Traumatic Stress in Women: Psychological Profile and Intervention | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 174 studies in Chronic Pain with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic spinal pain is a multifaceted condition frequently characterized by an absence of discernible structural causes, manifesting in symptoms such as significant disability and diminished quality of life. Persistent Spinal Pain Syndrome Type 2 (PSPS-T2) represents a common variant, implicating both peripheral and central nervous system mechanisms. This study investigates the synergistic effects of transcranial direct current stimulation (tDCS) in conjunction with motor control exercises on PSPS-T2 patients who have not responded to conventional treatments. A randomized controlled trial (RCT) will be conducted to compare an experimental group (tDCS + exercise) with a control group (exercise only), with the objective of enhancing functionality, alleviating pain levels, and improving psychological well-being. The findings may contribute to the development of more effective, patient-centered treatment strategies.
Chronic spinal pain, characterized by persistent discomfort, frequently lacks discernible structural abnormalities and represents a complex, multifactorial condition. This disorder, manifested by symptoms such as lumbar pain, severe disability, diminished quality of life, and elevated unemployment rates, poses a substantial challenge for treatment. Therapeutic strategies encompass surgical intervention, pharmacological treatments, and conservative methods emphasizing exercise and behavioral therapies. However, the heterogeneous nature of these patients complicates both diagnosis and the assessment of clinical outcomes. Among the diagnostic terms for chronic spinal pain, Persistent Spinal Pain Syndrome (PSPS), particularly PSPS-T2, has garnered attention due to its high prevalence and recurrence in clinical pain management. The complexity of PSPS necessitates a multidisciplinary approach, with a recent shift towards patient-centered care, which has proven effective in reducing both direct and indirect costs associated with these patients. PSPS-T2 has the potential to affect a significant portion of the population, influenced by biological, psychological, and social components. The condition's neuroplasticity involves both peripheral and central mechanisms, which alter the central nervous system's state, contributing to the persistence of pain. Recent advancements in neuromodulatory strategies, such as non-invasive brain stimulation (NIBS), have shown promise in treating spinal pain, particularly in cases associated with neuropathic pain and comorbidities like depression. Additionally, motor control exercises and spinal stabilization have demonstrated efficacy in reducing pain and disability, supporting self-management and improving biopsychosocial beliefs. Combining exercise with NIBS may enhance outcomes, offering an alternative for patients resistant to conventional treatments. This study aims to evaluate the effects of combining neuromodulation (tDCS) with motor control exercises in PSPS-T2 patients. Specifically, we hypothesize that this combined intervention will lead to improvements in functionality, pain reduction, and psychological outcomes, benefiting patients who have not responded to other treatments. A randomized controlled trial (RCT) will be conducted with two groups: an experimental group receiving both tDCS and exercise, and a control group receiving only exercise. The primary objective is to assess baseline characteristics and the effects of the intervention on functionality, pain, psychosocial variables, depression, and quality of life. Secondary objectives include identifying clinical profiles and evaluating the impact of gender, age, and BMI on treatment outcomes. This study is expected to provide valuable insights into the efficacy of combined neuromodulation and exercise for managing PSPS-T2, with potential applications in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The transcranial direct current stimulation (tDCS) group will undergo 20 minutes of continuous stimulation at an intensity of 1.5 mA over the left dorsolateral prefrontal cortex (DLPFC) during each session. Two saline-soaked sponge electrodes, each measuring 35 cm², will be utilized. In accordance with the international 10-20 EEG electrode placement system, the anodal electrode will be positioned over F3 to specifically target the left DLPFC. The reference electrode will be placed over the left eye to ensure that the current traverses the prefrontal area. A 30-second ramp-up period will be implemented at the commencement of the tDCS stimulation, followed by a 30-second ramp-down period at its conclusion.
Procedure: Exercise · Procedure: TDCS
The device will be configured to produce an upward gradient for 30 seconds, identical to that used in the experimental group, followed by a downward gradient for another 30 seconds. Consequently, the control group will feel a similar tingling on their scalp as the experimental group. This stimulation will occur for a total of 60 seconds, which is insufficient to induce changes in cortical excitability. Studies have demonstrated that this approach effectively ensures patient blinding .
Procedure: Exercise · Procedure: ShamTDCS
Structured treatment sessions, each lasting 30 minutes, will be organized into distinct blocks. In the initial phases, participants will engage in exercises emphasizing core stabilization and general strength training, with a particular focus on forced expiration as a technique to ensure the proper activation of the transversus abdominis muscle. This methodology aims to mitigate adverse effects associated with increased intra-abdominal pressure. To optimize the activation of the transversus abdominis, patients will be instructed to perform a forced expiration while concurrently drawing the navel inward and upward toward the spine, maintaining the lumbar spine in a neutral position. During the initial exercises, ultrasound imaging of the transversus abdominis will be employed as visual feedback, enabling patients to observe muscle thickening during forced expiration. This visual feedback enhances the accuracy of muscle activation and exercise technique. Exercises will be progressively s
The transcranial direct current stimulation (tDCS) protocol will involve the application of a continuous current for 30 minutes, with an intensity ranging from 1 to 1.5 mA, targeting the left dorsolateral prefrontal cortex (DLPFC) during each session. Two saline-soaked sponge electrodes, each measuring 35 cm², will be employed to ensure adequate skin contact. In accordance with the international 10-20 EEG electrode placement system, the anodal electrode will be positioned at the F3 location, specifically targeting the left DLPFC. The reference electrode will be placed above the left eye to facilitate efficient current flow through the prefrontal region of the brain. To enhance both safety and efficacy, a 30-second ramp-up and ramp-down period will be incorporated at the commencement and conclusion of the stimulation session. This methodology is intended to minimize potential adverse effects and ensure an optimal stimulation experience for participants.
The device will be configured to produce an upward gradient for 30 seconds, identical to that used in the experimental group, followed by a downward gradient for another 30 seconds. Consequently, the control group will feel a similar tingling on their scalp as the experimental group. This stimulation will occur for a total of 60 seconds, which is insufficient to induce changes in cortical excitability. Studies have demonstrated that this approach effectively ensures patient blinding.
The Oswestry Disability Index (ODI)
The Oswestry Disability Index (ODI) is the most widely used and validated assessment tool for low back pain. It is a self-administered questionnaire divided into ten sections designed to evaluate limitations in activities of daily living. Each section is scored on a scale from 0 to 5, with 5 indicating the highest level of disability. The total index score is calculated by dividing the sum of the section scores by the maximum possible score and multiplying by 100, yielding a percentage. The ODI has been validated in Spanish, demonstrating high sensitivity and specificity for functional assessment.
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
Tampa Scale 11 (TSK-11)
Kinesiophobia is defined as an excessive, irrational, and debilitating fear of physical movement and activity, stemming from a perceived vulnerability to a painful injury or reinjury. Fear of movement has been associated with disability in individuals with chronic pain. The Tampa Scale for Kinesiophobia (TSK) has been shown to predict the degree of disability in patients with chronic pain, with its scores correlating with depression, pain-related fear, and perceived pain intensity. Recently, the use of the TSK-11, a shortened version designed to identify fear-avoidance beliefs in musculoskeletal pain populations, has been recommended. The TSK-11 is scored between 11 and 44 points, with higher scores indicating greater fear of reinjury due to movement. The scale has demonstrated a 90% confidence interval and a reliability coefficient of 0.84.
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
Catastrophizing
Catastrophizing is understood as a set of negative emotional and cognitive processes that, by themselves, lead to an increase in pain symptoms and fatigue. It also involves a perceived helplessness in coping with pain and an inability to disengage from pain-related thoughts, whether in anticipation or recollection of the painful experience. Catastrophizing comprises three components: rumination, which refers to persistent worry and the inability to suppress thoughts related to pain; magnification, the tendency to exaggerate the unpleasantness of pain and amplify negative thoughts about pain relief; and helplessness, which arises from the perceived inability to cope with painful situations. To measure the level of catastrophizing in the present study, the Spanish validated version of the Pain Catastrophizing Scale (PCS) was used. This version demonstrates an internal consistency of 0.79 and a test-retest reliability of 0.84. The PCS is a self-administered questionnaire consisting of 1
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
SF-12
The SF-12 measures Health-Related Quality of Life (HRQoL) and comprises several dimensions: (a) physical functioning, (b) physical role, (c) emotional role, (d) social functioning, (e) bodily pain, and (f) vitality. Additionally, it includes two overarching dimensions that encompass the previous ones: (a) general health and (b) mental health. It is a widely used instrument in the healthcare field and has demonstrated satisfactory psychometric properties, including internal consistency and test-retest reliability.
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
Visual Analogue Scale (VAS)
The VAS is considered the most representative scale and is regarded as the best option due to its simplicity and ease of use. The version employed in this study ranges from 0 to 10. This scale provides an effective tool for subjectively and discriminatively quantifying pain intensity. A score of 0 indicates no pain as reported by the individual, while 10 represents the worst imaginable pain. Due to these characteristics, the VAS has shown greater utility compared to descriptive or fixed-value scales. The VAS has demonstrated high reliability (Cronbach's α = 0.97) \[95% CI = 0.96 to 0.98\].
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
DN4 Questionnaire
The DN4 is one of the most sensitive questionnaires for diagnosing neuropathic pain, demonstrating a high capacity to distinguish between neuropathic and nociceptive pain. The DN4 has been validated in patients with low back pain (LBP) due to disc herniation, spinal stenosis, degenerative disc disease, spinal pain, lumbar spine degeneration, spinal surgery, and lumbar scoliosis. A DN4 cutoff score of 4 yielded a sensitivity of 80% and a specificity of 92% for the diagnosis of neuropathic pain in individuals with LBP. Each patient was asked to describe their pain using the first seven descriptors of neuropathic pain in the DN4, in order to calculate the DN4 interview subscore (range: 0-7).
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
Beck Depression Inventory
The Beck Depression Inventory - Second Edition (BDI-II) is a self-report instrument consisting of 21 items used to measure the severity of depression in adults and adolescents over the age of 13. This version of the inventory (BDI-II) was developed to assess symptoms corresponding to the criteria for diagnosing depressive disorders outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV; 1994)
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
The Chronic Pain Self-Efficacy Questionnaire by Martín-Aragón
For this reason, a scale was designed to evaluate self-efficacy expectations regarding symptom management, physical functioning, and pain control. The Chronic Pain Self-Efficacy Questionnaire by Martín-Aragón et al. (1998), validated in Spanish, was used, as its validation results are comparable to those of the original scale by Anderson et al. (1995). This version demonstrates high internal consistency (α = 0.87). The questionnaire consists of 19 items, uses a Likert-type scale, and has a response range from 0 to 10, where 0 represents feeling completely incapable, 5 moderately capable, and 10 fully capable.
Time frame: Pre-treatment, 1-month follow-up, 3-month follow-up, 6-month follow-up
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 10 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Universidad Católica de Valencia San Vicente Mártir